Cargando…
Quantification of HER family receptors in breast cancer
The clinical success of trastuzumab in breast cancer taught us that appropriate tumor evaluation is mandatory for the correct identification of patients eligible for targeted therapies. Although HER2 protein expression by immunohistochemistry (IHC) and gene amplification by fluorescence in situ hybr...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389676/ https://www.ncbi.nlm.nih.gov/pubmed/25887735 http://dx.doi.org/10.1186/s13058-015-0561-8 |
_version_ | 1782365601288683520 |
---|---|
author | Nuciforo, Paolo Radosevic-Robin, Nina Ng, Tony Scaltriti, Maurizio |
author_facet | Nuciforo, Paolo Radosevic-Robin, Nina Ng, Tony Scaltriti, Maurizio |
author_sort | Nuciforo, Paolo |
collection | PubMed |
description | The clinical success of trastuzumab in breast cancer taught us that appropriate tumor evaluation is mandatory for the correct identification of patients eligible for targeted therapies. Although HER2 protein expression by immunohistochemistry (IHC) and gene amplification by fluorescence in situ hybridization (FISH) assays are routinely used to select patients to receive trastuzumab, both assays only partially predict response to the drug. In the case of epidermal growth factor receptor (EGFR), the link between the presence of the receptor or its amplification and response to anti-EGFR therapies could not be demonstrated. Even less is known for HER3 and HER4, mainly due to lack of robust and validated assays detecting these proteins. It is becoming evident that, besides FISH and IHC, we need better assays to quantify HER receptors and categorize the patients for individualized treatments. Here, we present the current available methodologies to measure HER family receptors and discuss the clinical implications of target quantification. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-015-0561-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4389676 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43896762015-04-09 Quantification of HER family receptors in breast cancer Nuciforo, Paolo Radosevic-Robin, Nina Ng, Tony Scaltriti, Maurizio Breast Cancer Res Review The clinical success of trastuzumab in breast cancer taught us that appropriate tumor evaluation is mandatory for the correct identification of patients eligible for targeted therapies. Although HER2 protein expression by immunohistochemistry (IHC) and gene amplification by fluorescence in situ hybridization (FISH) assays are routinely used to select patients to receive trastuzumab, both assays only partially predict response to the drug. In the case of epidermal growth factor receptor (EGFR), the link between the presence of the receptor or its amplification and response to anti-EGFR therapies could not be demonstrated. Even less is known for HER3 and HER4, mainly due to lack of robust and validated assays detecting these proteins. It is becoming evident that, besides FISH and IHC, we need better assays to quantify HER receptors and categorize the patients for individualized treatments. Here, we present the current available methodologies to measure HER family receptors and discuss the clinical implications of target quantification. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-015-0561-8) contains supplementary material, which is available to authorized users. BioMed Central 2015-04-09 2015 /pmc/articles/PMC4389676/ /pubmed/25887735 http://dx.doi.org/10.1186/s13058-015-0561-8 Text en © Nuciforo et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Nuciforo, Paolo Radosevic-Robin, Nina Ng, Tony Scaltriti, Maurizio Quantification of HER family receptors in breast cancer |
title | Quantification of HER family receptors in breast cancer |
title_full | Quantification of HER family receptors in breast cancer |
title_fullStr | Quantification of HER family receptors in breast cancer |
title_full_unstemmed | Quantification of HER family receptors in breast cancer |
title_short | Quantification of HER family receptors in breast cancer |
title_sort | quantification of her family receptors in breast cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389676/ https://www.ncbi.nlm.nih.gov/pubmed/25887735 http://dx.doi.org/10.1186/s13058-015-0561-8 |
work_keys_str_mv | AT nuciforopaolo quantificationofherfamilyreceptorsinbreastcancer AT radosevicrobinnina quantificationofherfamilyreceptorsinbreastcancer AT ngtony quantificationofherfamilyreceptorsinbreastcancer AT scaltritimaurizio quantificationofherfamilyreceptorsinbreastcancer |